Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium Chemical Properties: Comprehensive Analysis For Pharmaceutical Formulation Development

NOV 17, 202663 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose Sodium, a crosslinked polymer derivative of carboxymethylcellulose sodium, represents a critical pharmaceutical excipient widely employed in oral solid dosage forms. Its unique chemical structure—characterized by internal crosslinking of carboxymethyl substituents—imparts exceptional disintegration, swelling, and moisture management properties that are essential for optimizing drug release kinetics and formulation stability 12. Understanding the chemical properties of Croscarmellose Sodium is fundamental for formulators seeking to enhance bioavailability, ensure product consistency, and meet stringent regulatory standards in modern pharmaceutical development.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Crosslinking Chemistry Of Croscarmellose Sodium

Croscarmellose Sodium is synthesized through the controlled crosslinking of sodium carboxymethylcellulose, typically achieved via self-crosslinking reactions catalyzed by dilute sulfuric acid in aqueous-organic solvent systems 7. The parent polymer, carboxymethylcellulose sodium, possesses a degree of substitution (DS) ranging from 0.60 to 0.90, which defines the average number of carboxymethyl groups per anhydroglucose unit 17. During crosslinking, ester or ether bridges form between carboxymethyl groups on adjacent polymer chains, creating a three-dimensional network that is insoluble in water yet highly hydrophilic 24.

The crosslinking process is typically conducted in two stages: an initial reaction at 40–50°C for 0.5–2.0 hours, followed by a second stage at 65–75°C for 2.0–4.0 hours under acidic conditions (pH 2–4) 7. This biphasic approach allows precise control over crosslink density, which directly influences the material's swelling capacity, disintegration rate, and mechanical properties 17. The resulting polymer exhibits a fibrous, porous microstructure that facilitates rapid water uptake and capillary action—key mechanisms underlying its superior disintegrant performance 69.

Key structural features include:

  • Degree of Substitution (DS): 0.60–0.85 for pharmaceutical-grade material, ensuring optimal balance between hydrophilicity and crosslink stability 7
  • Crosslink Density: Controlled via reaction temperature, time, and catalyst concentration; higher crosslink density reduces swelling but enhances mechanical integrity 17
  • Molecular Weight Distribution: Polydisperse, with weight-average molecular weights typically in the range of 50,000–200,000 Da, though exact values depend on the cellulose source and processing conditions 2

The chemical stability of the crosslinked network is critical: ester-type crosslinks may be susceptible to hydrolysis under extreme pH or prolonged moisture exposure, whereas ether-type crosslinks offer superior long-term stability 410. Modern synthesis protocols favor conditions that maximize ether crosslinking to ensure product robustness across diverse storage environments 7.

Physicochemical Properties And Performance Characteristics

Hygroscopicity And Moisture Management

Croscarmellose Sodium is inherently hygroscopic, a property that profoundly influences both its functional performance and storage requirements 38. The crosslinked polymer matrix contains numerous hydrophilic carboxymethyl groups that readily form hydrogen bonds with water molecules, leading to rapid moisture uptake when exposed to humid environments 11. Equilibrium moisture content typically ranges from 5% to 10% by weight at 25°C and 60% relative humidity, though this can increase to 12–15% under high-humidity conditions (≥75% RH) 11.

The hygroscopic nature of Croscarmellose Sodium serves dual roles in pharmaceutical formulations:

  • Disintegration Enhancement: Absorbed moisture facilitates rapid swelling and capillary wicking within tablet matrices, accelerating disintegrant action upon contact with dissolution media 56
  • Formulation Stability Challenges: Excessive moisture uptake can compromise tablet hardness, promote chemical degradation of moisture-sensitive active pharmaceutical ingredients (APIs), and reduce flowability during manufacturing 11

To mitigate moisture-related issues, specialized storage protocols are recommended, including the use of desiccant-equipped containers, controlled-humidity environments (≤50% RH), and moisture-barrier packaging 11. Recent innovations include moisture-proof storage devices incorporating hot-air drying systems and desiccant balls to maintain optimal moisture levels during long-term storage 11.

Particle Size Distribution And Surface Area

Pharmaceutical-grade Croscarmellose Sodium is typically supplied as a fine powder with particle size distributions tailored to specific formulation needs. Standard grades exhibit a median particle diameter (d50) of 30–80 μm, while micronized variants offer d50 values below 20 μm for applications requiring enhanced surface area and faster disintegration kinetics 812. The material is routinely sieved through 200-mesh screens (74 μm openings) to ensure uniformity and eliminate oversized aggregates 7.

Surface area measurements by BET nitrogen adsorption typically yield values of 1.5–3.5 m²/g for standard grades and 4–8 m²/g for micronized forms 8. Higher surface area correlates with increased water uptake rates and more rapid tablet disintegration, making micronized Croscarmellose Sodium particularly valuable in fast-dissolving formulations and orally disintegrating tablets (ODTs) 56.

pH Stability And Chemical Reactivity

Croscarmellose Sodium demonstrates excellent chemical stability across a broad pH range (pH 3–9), making it compatible with most APIs and excipients encountered in oral solid dosage forms 24. The crosslinked structure resists dissolution and degradation under physiological pH conditions (pH 1.2 in gastric fluid, pH 6.8 in intestinal fluid), ensuring consistent disintegrant performance throughout the gastrointestinal tract 610.

However, prolonged exposure to extreme acidic (pH <2) or alkaline (pH >10) conditions may induce gradual hydrolysis of ester crosslinks, leading to partial depolymerization and loss of functional properties 410. Stability studies conducted under accelerated conditions (40°C/75% RH for 6 months) confirm that pharmaceutical compositions containing Croscarmellose Sodium maintain disintegration performance and chemical integrity when formulated within recommended pH ranges 2410.

The polymer is chemically inert toward most organic solvents, oxidizing agents, and reducing agents commonly used in pharmaceutical processing, though it may undergo slight discoloration upon prolonged exposure to strong oxidizers or UV radiation 4. No significant interactions with common lubricants (magnesium stearate, sodium stearyl fumarate), binders (hydroxypropyl methylcellulose, polyvinylpyrrolidone), or fillers (microcrystalline cellulose, lactose) have been reported under standard manufacturing conditions 3812.

Functional Mechanisms: Disintegration And Drug Release Enhancement

Swelling And Wicking Mechanisms

The primary functional mechanism of Croscarmellose Sodium as a tablet disintegrant involves rapid water uptake and volumetric expansion upon contact with aqueous media 56. When a tablet containing Croscarmellose Sodium is immersed in dissolution medium, water penetrates the porous polymer network via capillary action, causing the crosslinked chains to swell and exert disruptive forces on the tablet matrix 9. Swelling ratios (volume after swelling / initial volume) typically range from 4:1 to 10:1 depending on crosslink density and particle size 6.

Simultaneously, the fibrous morphology of Croscarmellose Sodium facilitates wicking—the rapid transport of water through interconnected capillary channels within the tablet structure 9. This dual mechanism of swelling and wicking generates internal stresses that overcome interparticulate cohesion, leading to rapid tablet disintegration into fine granules or primary particles 56. Disintegration times for tablets containing 6–14% w/w Croscarmellose Sodium typically fall within 30 seconds to 3 minutes in standard USP dissolution apparatus, significantly faster than formulations employing alternative disintegrants such as starch or sodium starch glycolate 56.

Concentration-Dependent Performance

The disintegrant efficacy of Croscarmellose Sodium exhibits a concentration-dependent relationship, with optimal performance typically observed at 6–14% w/w in tablet formulations 5612. At concentrations below 5% w/w, disintegration may be incomplete or delayed, particularly in formulations with high compaction pressures or hydrophobic APIs 5. Conversely, concentrations exceeding 15% w/w offer diminishing returns and may compromise tablet hardness, increase friability, or interfere with drug release kinetics 612.

Specific concentration recommendations include:

  • Standard Immediate-Release Tablets: 8–12% w/w for balanced disintegration and mechanical strength 56
  • Orally Disintegrating Tablets (ODTs): 10–14% w/w to achieve disintegration times <30 seconds 56
  • High-Dose Formulations: 6–8% w/w to minimize excipient load while maintaining adequate disintegration 12
  • Moisture-Sensitive APIs: 5–7% w/w combined with moisture-barrier packaging to reduce hygroscopic effects 312

Formulation scientists must balance disintegrant concentration against other critical quality attributes, including tablet hardness (typically 50–100 N for conventional tablets), friability (<1.0%), and content uniformity 3812.

Synergistic Effects With Other Excipients

Croscarmellose Sodium demonstrates synergistic interactions with several classes of pharmaceutical excipients, enabling formulators to optimize both disintegration and drug release profiles 3812. Notable synergies include:

  • Hydroxypropyl Methylcellulose (HPMC): Co-processing with HPMC (2–5% w/w) enhances granule cohesion during wet granulation while preserving rapid disintegration, particularly beneficial for poorly compressible APIs 3812
  • Microcrystalline Cellulose (MCC): Blending Croscarmellose Sodium with MCC (40–60% w/w) provides excellent compressibility and disintegration, forming the basis of many direct-compression formulations 3812
  • Micronized Crosslinked Polyvinylpyrrolidone (Crospovidone): Dual-disintegrant systems combining Croscarmellose Sodium (5–7% w/w) and crospovidone (2–4% w/w) achieve ultra-fast disintegration (<15 seconds) in ODT applications 3812
  • Colloidal Silicon Dioxide: Addition of 0.2–0.5% w/w colloidal silicon dioxide improves powder flowability and reduces moisture-induced caking without compromising disintegrant function 812

These synergistic combinations are particularly valuable in formulations containing hydrophobic or poorly water-soluble APIs, where enhanced wetting and dispersion are critical for achieving adequate bioavailability 38.

Preparation Methods And Quality Control Parameters

Synthesis Routes And Process Optimization

The industrial synthesis of Croscarmellose Sodium follows a controlled solvent-based crosslinking process designed to meet stringent pharmacopeial specifications 17. The standard protocol involves:

  1. Dispersion: Sodium carboxymethylcellulose (DS 0.8–0.9) is dispersed in a mixed solvent system (typically isopropanol:water at 10:1 v/v) at room temperature with continuous stirring 7
  2. Heating: The dispersion is heated to 40–50°C to facilitate polymer chain mobility and uniform catalyst distribution 7
  3. pH Adjustment: Sulfuric acid (15–30% w/w) is added to adjust pH to 2–4, initiating the crosslinking reaction 17
  4. Two-Stage Crosslinking: Stage 1 proceeds at 40–50°C for 0.5–2.0 hours to establish initial crosslinks; Stage 2 continues at 65–75°C for 2.0–4.0 hours to complete network formation 7
  5. Neutralization And Washing: The reaction mixture is filtered, and the filter cake is sequentially washed with water, saturated sodium bicarbonate solution (to neutralize residual acid), water again, and finally 60% ethanol (twice) to remove soluble impurities 7
  6. Drying And Milling: The washed product is dried at 70–90°C, milled, and sieved through a 200-mesh screen to achieve the desired particle size distribution 7

Critical process parameters include:

  • Reaction Temperature: Precise control within ±2°C ensures reproducible crosslink density 7
  • pH Control: Maintaining pH 2–4 throughout crosslinking prevents over-crosslinking (which reduces swelling) or under-crosslinking (which compromises mechanical integrity) 17
  • Solvent Ratio: The 10:1 isopropanol:water ratio optimizes polymer dispersion while minimizing side reactions 7
  • Washing Efficiency: Thorough removal of residual sulfuric acid and soluble oligomers is essential to meet pharmacopeial purity standards (<0.5% sulfated ash) 7

Alternative synthesis routes employing propylene glycol as a crosslinking agent have been reported, offering milder reaction conditions and potentially improved biocompatibility, though these methods are less widely adopted in commercial production 1.

Pharmacopeial Specifications And Analytical Methods

Croscarmellose Sodium must comply with specifications outlined in major pharmacopeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Chinese Pharmacopoeia (ChP) 17. Key quality attributes and test methods include:

  • Identification: Infrared spectroscopy (IR) confirms characteristic absorption bands at 1600–1640 cm⁻¹ (carboxylate C=O stretch) and 1050–1150 cm⁻¹ (C-O-C ether stretch) 7
  • Degree of Substitution (DS): Determined by back-titration of carboxymethyl groups; acceptable range 0.60–0.85 17
  • pH (1% Aqueous Slurry): 5.0–7.5, ensuring compatibility with most APIs 7
  • Loss on Drying: ≤10.0% (105°C, 3 hours), reflecting equilibrium moisture content 7
  • Residue on Ignition (Sulfated Ash): ≤30.0%, primarily sodium salts and inorganic impurities 7
  • Heavy Metals: ≤20 ppm (as Pb), determined by atomic absorption spectroscopy 7
  • Microbial Limits: Total aerobic count ≤1000 CFU/g; yeast and mold ≤100 CFU/g; absence of E. coli and Salmonella 7
  • Swelling Capacity: Volumetric expansion ≥4-fold in water, assessed by graduated cylinder method 6

Advanced characterization techniques employed in R&D settings include:

  • Scanning Electron Microscopy (SEM): Reveals fibrous morphology and pore structure 9
  • Differential Scanning Calorimetry (DSC): Detects glass transition (Tg ≈ 60–80°C) and thermal degradation onset (≥250°C) 4
  • Thermogravimetric Analysis (TGA): Quantifies moisture content and thermal stability profile 4
  • X-Ray Diffraction (XRD): Confirms amorphous nature of the crosslinked polymer 2
  • Fourier-Transform Infrared Spectroscopy (FTIR): Monitors crosslink formation and detects residual functional groups 7

Applications In Pharmaceutical Formulation Development

Immediate-Release Tablets And Capsules

Croscarmellose Sodium is the disintegrant of choice for immediate-release (IR) tablets and capsules, where rapid drug release is essential for achieving therapeutic plasma concentrations within 30–60 minutes post-administration 56. Typical formulations incorporate 8–12% w/w Croscarmellose Sodium, blended with APIs, fillers (lactose, microcrystalline cellulose), binders (HPMC, PVP), and lubricants (magnesium stearate) 3812.

**Case Study: Entacap

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
ORION CORPORATIONImmediate-release oral tablets for Parkinson's disease treatment requiring fast therapeutic plasma concentrations and enhanced dissolution of poorly water-soluble active pharmaceutical ingredients.Entacapone TabletsCroscarmellose sodium at 10-14% w/w significantly increases drug release rate and achieves rapid disintegration within 30 seconds to 3 minutes, enhancing bioavailability of catechol derivatives.
F. HOFFMANN-LA ROCHE AGOral solid dosage forms for cholesteryl ester transfer protein inhibitors requiring moisture management, chemical stability, and controlled drug release in cardiovascular therapeutics.CETP Inhibitor FormulationsHygroscopic polymer matrix containing 5-7% croscarmellose sodium provides chemical protection and physical stability for hydrophobic water-instable compounds while maintaining rapid disintegration properties.
ANHUI SHANHE PHARMACEUTICAL EXCIPIENTS CO. LTD.Production of pharmaceutical excipients for tablet disintegration applications requiring precise crosslink density control, optimal hydrophilicity, and compliance with pharmacopeial specifications.Pharmaceutical-Grade Croscarmellose SodiumTwo-stage crosslinking synthesis at controlled temperatures (40-75°C) and pH 2-4 produces material with degree of substitution 0.60-0.85, achieving superior swelling capacity (4-10 fold) and meeting National Pharmacopoeia standards.
R.P. SCHERER TECHNOLOGIES INC.Orally disintegrating tablets and pediatric formulations requiring palatability enhancement without compromising fast disintegration and immediate drug release characteristics.Taste-Masked Pharmaceutical FormulationsCroscarmellose sodium coating on bitter-tasting active agents provides effective taste masking while preserving rapid tablet disintegration properties through fluidized bed coating process.
GUANGZHOU TIANRUN PHARMACEUTICAL CO. LTD.Long-term storage and handling of hygroscopic croscarmellose sodium in pharmaceutical manufacturing facilities requiring moisture control to maintain disintegrant performance and chemical stability.Moisture-Proof Storage SystemIntegrated hot-air drying and desiccant ball system maintains optimal moisture content below 10% w/w at controlled humidity (≤50% RH), preventing hygroscopic degradation and preserving functional properties.
Reference
  • Sodium croscarmellose and preparation method thereof
    PatentInactiveCN104262649A
    View detail
  • Pharmaceutical composition comprising 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid
    PatentInactiveNZ534471B
    View detail
  • A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium
    PatentActiveIL225780A0
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png